More Evidence for Lower Ribociclib Dose in Advanced Breast Cancer

(MedPage Today) — A lower dose of the CDK4/6 inhibitor ribociclib (Kisqali) managed toxicity without compromising efficacy for women with hormone receptor (HR)-positive/HER2-negative breast cancer, according to results from two studies.
A phase…